Oregon to Hold First-Ever Hearing on Adding Female Orgasmic Disorder to Medical Marijuana Program

OG article by Anthony Martinelli

January 20, 2026

Oregon will hold its first-ever hearing February 3-5 on adding Female Orgasmic Disorder (FOD) as a qualifying condition for the Medical Marijuana Program. Petitioner Rebecca Andersson appealed her denial by the Oregon Health Authority, arguing scientific evidence shows cannabis mitigates symptoms with benefits outweighing risks. Critics say the authority used an overly strict standard requiring randomized trials not mandated by rules. The hearing features 12 experts in cannabinoid medicine, gynecology, psychiatry, neuroscience, and women's health. FOD affects up to 41% of women, often tied to trauma, anxiety, depression, and stress, with no FDA-approved treatments. Studies indicate cannabis improves orgasmic function and reduces distress. Supporters, including the Female Orgasm Research Institute, call it a landmark for women's health and cannabis policy. Illinois and Connecticut already approve it; New Mexico advances similar efforts. Oregon's decision could influence national standards. The medical program provides lower taxes, higher possession limits, home cultivation, and protections for patients under 21, separate from adult-use rules.